Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report | BMC Cancer | Full Text

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report | BMC Cancer | Full Text

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report

A BRAF V600E mutation is found as driver oncogene in patients with non-small cell lung cancer. Although combined treatment with dabrafenib and trametinib is highly effective, the efficacy of reduced doses of the ...

Authors:Yuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, Sakiko Ootani, Azusa Tanimoto, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi and Seiji Yano

Citation:BMC Cancer 2020 20:156

Content type:Case report

Published on: 24 February 2020

• ViewFull Text
 
• ViewPDF